Exploratory Clinical Neuroscience Research on Substance Use Disorders
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This contract opportunity from the National Institutes of Health, under the Department of Health and Human Services, seeks to fund exploratory clinical neuroscience research focused on substance use disorders (SUD). It employs a phased innovation award mechanism (R61/R33) designed to support projects that investigate the neurobiological mechanisms underlying SUD, including fundamental brain functions related to substance use. This mechanism is intended for developmental projects that require larger budgets than those typically allowed under the R21 grant, enabling more comprehensive and in-depth clinical research. The initiative encourages applications that are exploratory in nature and aim to deepen understanding of the brain’s role in substance use and addiction. It accommodates clinical trial options but remains primarily focused on neuroscience research related to drug abuse. The point of contact for inquiries is the Division of Neuroscience and Behavior, reachable via a designated NIH email. This funding opportunity was publicly announced in March 2026 and is accessible through the grants.gov portal.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This NOFO is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)
